92 related articles for article (PubMed ID: 15767607)
1. A man whose scapula was spared a drug-associated rash.
Sanz A; del Valle ML
CMAJ; 2005 Mar; 172(6):745. PubMed ID: 15767607
[No Abstract] [Full Text] [Related]
2. Erlotinib induced skin rash spares skin in previous radiotherapy field.
Mitra SS; Simcock R
J Clin Oncol; 2006 Jun; 24(16):e28-9. PubMed ID: 16735697
[No Abstract] [Full Text] [Related]
3. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
4. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
5. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Chiu HY; Cheng YP; Jee SH; Tsai TF
Clin Exp Dermatol; 2012 Dec; 37(8):922-4. PubMed ID: 22731795
[No Abstract] [Full Text] [Related]
6. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
7. Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Lin TC; Wu PY
Cutis; 2011 Dec; 88(6):281-3. PubMed ID: 22372166
[No Abstract] [Full Text] [Related]
8. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Ding K; Pater J; Whitehead M; Seymour L; Shepherd FA
Contemp Clin Trials; 2008 Jul; 29(4):527-36. PubMed ID: 18280222
[TBL] [Abstract][Full Text] [Related]
9. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib-induced dermatologic side-effects.
Bovenschen HJ; Alkemade JA
Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
[No Abstract] [Full Text] [Related]
11. Purpuric drug eruption and alopecia induced by erlotinib.
Nakamura-Wakatsuki T; Yamamoto T
Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
[TBL] [Abstract][Full Text] [Related]
12. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
13. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
[TBL] [Abstract][Full Text] [Related]
14. [Acneiforme rash in woman with pulmonary adenocarcinoma].
Navarro Martín M; Rodríguez Sánchez C; Delgado Fernández C; Mezquita Pérez L; Cruz Hernández JJ
Rev Clin Esp; 2008 May; 208(5):251-2. PubMed ID: 18457638
[No Abstract] [Full Text] [Related]
15. Exfoliative eruption secondary to gefitinib (ZD1839).
Becuwe C; Dalle S; Arpin D; Balme B; Thomas L
Dermatology; 2007; 215(3):266-8. PubMed ID: 17823530
[No Abstract] [Full Text] [Related]
16. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib-induced skin manifestations.
Motoki T; Mitsuishi T; Kawana S
J Dermatol; 2009 Dec; 36(12):658-9. PubMed ID: 19958452
[No Abstract] [Full Text] [Related]
18. Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Sheen YS; Hsiao CH; Chu CY
Arch Dermatol; 2008 Feb; 144(2):269-70. PubMed ID: 18283195
[No Abstract] [Full Text] [Related]
19. A case of bullous dermatitis induced by erlotinib.
Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
[TBL] [Abstract][Full Text] [Related]
20. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Pascual JC; Belinchón I; Sivera F; Yuste A
Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
